Re: Collaboration

ReNeuron Group plc
18 May 2007


ReNeuron announces collaboration to enhance its stem cell expansion technology



Guildford, UK, 18 May 2007: ReNeuron Group plc (LSE: RENE.L) today announced
that it has signed a Research Collaboration Agreement with King's College London
to further develop the Company's c-mycER stem cell expansion technology. The
research will be part-funded by the UK government under its Knowledge Transfer
Partnership (KTP) scheme.



Dr Michael Antoniou, who heads the Nuclear Biology Group in the Department of
Medical and Molecular Genetics at King's, will develop new delivery constructs
to enhance the efficiency and safety of the c-mycER transgene when used to grow
stem cell lines.



Dr John Sinden, Chief Scientific Officer of ReNeuron, said:



'We have already successfully scaled up our ReN001 cell line for stroke using
our c-mycER platform. Having demonstrated that the technology works well in our
lead therapeutic programme, we are looking to this collaboration to enhance
efficiency when selecting and scaling future cell line products using c-mycER.
We believe this will ultimately lead to shorter therapeutic development
timelines for ReNeuron's stem cell therapies. The UK government's support for
this collaboration through the KTP scheme will assist in ensuring that the
programme realises its aims in the shortest possible timeframe.'



Enquiries:

ReNeuron
Michael Hunt, Chief Executive Officer                   Tel: [phone]
Dr John Sinden, Chief Scientific Officer

Financial Dynamics
David Yates                                            Tel: [phone]
Nicola Daley



Notes to Editors



About ReNeuron

ReNeuron is a leading, UK-based stem cell therapy business. It is applying its
novel stem cell platform technologies in the development of ground-breaking stem
cell therapies to serve significant and unmet or poorly-met clinical needs.



ReNeuron has used its c-mycER technology to generate genetically stable neural
stem cell lines. This technology platform has multi-national patent protection
and is fully regulated by means of a chemically-induced safety switch. Cell
growth can therefore be completely arrested prior to in vivo implantation.



ReNeuron has filed for approval to commence initial clinical studies in the US
with its lead ReN001 stem cell therapy for chronic stroke disability. This
represents the world's first such filing concerning a neural stem cell treatment
for a major neurological disorder. ReNeuron has also generated pre-clinical
efficacy data with its ReN005 stem cell therapy for Huntington's disease, a
genetic and fatal neurodegenerative disorder that affects around 1 in 10,000
people.  This programme is in pre-clinical development. In addition to its
stroke and Huntington's disease programmes, ReNeuron is developing stem cell
therapies for Parkinson's disease, Type 1 diabetes and diseases of the retina.



ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcellTM range of cell lines for use in research and in drug
discovery applications in the pharmaceutical industry. ReNeuron's ReNcellTM CX
and ReNcellTM VM neural cell lines are marketed worldwide under license by
Millipore Corporation.



ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.



Further information on ReNeuron and its products can be found at
www.reneuron.com.



About King's College London
King's College London is the fourth oldest university in England with more than
13,700 undergraduates and nearly 5,600 graduate students in nine schools of
study based at five London campuses. It is a member of the Russell Group: a
coalition of the UK's major research-based universities. The College has had 24
of its subject-areas awarded the highest rating of 5* and 5 for research
quality, demonstrating excellence at an international level, and it has recently
received an excellent result in its audit by the Quality Assurance Agency.



King's has a particularly distinguished reputation in the humanities, law,
international relations, medicine, nursing and the sciences, and has played a
major role in many of the advances that have shaped modern life, such as the
discovery of the structure of DNA. It is the largest centre for the education
of healthcare professionals in Europe and is home to five Medical Research
Council Centres - more than any other university.



King's is in the top group of UK universities for research earnings, with income
from grants and contracts of more than £100 million, and has an annual turnover
of more than £363 million.





Data sources: UK Stroke Association; American Stroke Association.



This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.



The terms 'ReNeuron', 'the Company' or 'the Group' used in this statement refer
to ReNeuron Group plc and/or its subsidiary undertakings, depending on the
context.


                      This information is provided by RNS
            The company news service from the London Stock Exchange